Effect of C2 ceramide on the inositol phospholipid metabolism (uptake of 32P, 3H-serine and 3H-palmitic acid) and apoptosis-related morphological changes in Tetrahymena

Sphingomyelin metabolites have significant role in the regulation of many life processes of mammalian cells. In the present experiments the influence of phospholipid turnover and apoptosis related morphologic signs by one of this metabolite, C2 ceramide was studied, and compared to the control, untreated cells, in the unicellular Tetrahymena. The incorporation of phospholipid head group components (serine, phosphorus) show a clear time-dependence; while the incorporation of fatty acid component (palmitic acid) is very fast: no significant alterations were found between 5- and 60-min incubations. C2 ceramide treatment didn't alter 3H-palmitic acid incorporation into phospholipids, however 3H-serine incorporation was mainly inhibited. The amount of total incorporated 32P was also decreased, on the other hand the lover concentration C2 ceramide (10 microM) elevated the synthesis of inositol phospholipids. The higher concentration of C2 ceramide (50 microM) had inhibitory effect on the synthesis of each phospholipids examined. This means that in the presence of the C2 ceramide the synthesis, recovery and turnover of phospholipids, participating in signal transduction, are altered. However these observations were based the uptake of labeled phospholipid precursors, which gives information on the dynamics of the process, without using lipid mass measurements. C2 ceramide also caused the rounding off the cells, DNA degradation and nuclear condensation. These latter observations point to morphological signs of apoptosis. The results call attention to the role of sphingomyelin metabolites on signalization of unicellulars, to the cross-talk between the inositol phospholipids and sphingomyelin metabolites, and the role of these molecules in the apoptotic processes at a low evolutionary level.     

Chlamydophila (Chlamydia) pneumoniae induces histidine decarboxylase production in the mouse lung

Chlamydophila (Chlamydia) pneumoniae (C. pneumoniae) is the third most common cause of community-acquired pneumonia and is probably involved in the development of certain chronic inflammatory diseases, including atherosclerosis and adult-onset asthma. Histamine, synthesized by histidine decarboxylase (HDC) from L-histidine, plays an essential role in allergic and inflammatory processes and in cell differentiation. The effect of C. pneumoniae infection on the expression of HDC has not been examined. In the present study, normal Balb/c mice and HDC knockouts, and control mice with a CD1 background were infected intranasally with C. pneumoniae. On days 1, 3, 7, 16 and 31 after infection, the normal Balb/c mice were sacrificed and divided into three groups. In the homogenized lungs of the first group, C. pneumoniae titres were determined and demonstrated peak levels on day 7. HDC production was revealed by a Western blot assay throughout the observation period of 1-16 days, and cytokine concentrations were determined by ELISA. The interleukin-3 (IL-3) and interleukin-6 (IL-6) levels were highest on day 1 and on days 1-3, respectively; the interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) levels reached the maximum on day 7, but the quantity of IL-4 was still three times higher than that in the control group 16 days after infection. The lungs of the mice in the second group were processed for the in situ demonstration of HDC activity, while the lungs in the third group were stained for C. pneumoniae antigen. The HDC activity was increased predominantly in the bronchial epithelial cells, while C. pneumoniae antigens were expressed especially in the interstitial macrophages. The HDC knockout mice exhibited a higher survival rate after C. pneumoniae infection than did the control mice. These results point to a strong association between local histamine production and other inflammatory mediators and are novel in demonstrating the role of histamine in the pathomechanism of C. pneumoniae infections.     

Impact of repeated bouts of eccentric exercise on myogenic gene expression

Evidence indicates that repeated-bouts of eccentric exercise (EE) do not exacerbate the extent of muscle damage indices, as compared to a single-bout. We hypothesized that molecular adaptations, under repeated-bouts of EE, would include suppression of muscle repair inhibitory factors such as myostatin and up-regulation of muscle repair positive regulatory factors such as myogenic regulatory factors (MRFs). Fifteen males were recruited for this study. The exercise group (n = 9) successfully completed six sets of 15 reps of maximum voluntary eccentric contractions, for six consecutive days, using a dynamometer (Multicont-II). Blood and muscle biopsy samples were obtained from each subject 1 week prior to exercise, 2 days post the first training session, and 24 h after the last training session. Gene expression levels were determined using real-time RT-PCR. Blood samples were analyzed for creatine kinase (CK) and lactate-dehydrogenase (LDH) activity. Repeated-bouts of EE induced a large down-regulation of myostatin mRNA (−73%) which persisted throughout the study. The responses of MRFs were mild. At day 3 only myogenin increased significantly (1.9 fold) while MyoD decreased by 45%. Surprisingly, at day 7, despite the presence of muscle damage indices, all MRFs returned to the pre-exercise levels. The results of the present study showed that repeated-bouts of EE, for six consecutive days, dramatically decreased Myostatin mRNA expression but impaired the expression patterns of MRFs such that, with the exception of myogenin that showed a moderate non-sustained increase, MyoD and MYf5 response was minimal. Grants: Funding was provided by the Ministry of Health of the Hungarian Government. Grant number: ETT 388/2003.     

Reciprocal inhibitory interactions between interferon γ and histamine in melanoma

BACKGROUND: Although protein kinase C (PKC) isoenzymes have been implicated as mediators for multiple physiological processes, PKC also mediates cellular and intestinal mucosal injury. We have investigated the expression of the isoenzymes, PKCalpha, PKCdelta, PKCepsilon and PKCzeta in colonic mucosal tissue from TNBS-treated and HLA-B27 spontaneous colitis animals. METHODS: Colonic mucosal samples were taken at various times (2 h-14 d) after instillation of TNBS (75 mg/kg in 50% ethanol) or from HLA-B27 rats at 16-18 weeks of age. Tissues were homogenized and separated into membrane and cytosolic fractions by centrifugation. PKC activity was measured radioenzymatically. PKC protein for isoforms alpha, delta, epsilon and delta was assessed by Western blot while corresponding mRNA was analyzed by RT-PCR. RESULTS: PKC activity increased in cytosolic and membrane fractions by 1d after TNBS and returned to normal by d3. PKCalpha protein was translocated from cytosol to membrane by 2 h after TNBS followed by down-regulation until d3. Increases in PKCdelta, PKCepsilon and PKCzeta protein occurred initially in membrane fractions as early as 2 h after TNBS. Increases in cytosolic protein occurred at later times after induction of colitis. Protein levels for all isoenzymes remained increased up to 7d after TNBS. RT-PCR revealed that mRNA for PKCalpha decreased while PKC mRNA increased correspondingly with their respective protein levels. In HLA-B27 rats, protein levels for all isoforms were less than was detected in normal colonic tissue. Conclusions: The early increase in gene expression and protein levels for PKCalpha and zeta suggest that these isozymes may play roles in an acute model of colitis induced by TNBS. In contrast, the increase in PKCdelta and epsilon protein was not associated with mRNA changes suggesting that these isozymes are not similarly regulated in the inflamed colonic mucosa. In a chronic model of experimental colonic inflammation (HLA-B27), all of these isoforms appeared to be down-regulated.     

Increased histidine decarboxylase expression during in vitro monocyte maturation; a possible role of endogenously synthesised histamine in monocyte/macrophage differentiation

OBJECTIVE: In this study the expression of histidine decarboxylase (HDC), the pivotal enzyme in histamine formation and the effect of endogenously produced histamine on differentiation antigens was examined during in vitro differentiation of human monocytes. MATERIAL AND TREATMENT: Human elutriated monocytes from healthy volunteers were incubated with macrophage colony stimulating factor (M-CSF) and the expression of HDC was followed at both mRNA and protein levels. To study the possible function of histamine we followed the expression of some cell surface markers (CD14, CD16, CD91, CD49d and CD11c) relevant for phagocytic differentiation upon incubation in the presence of different histamine inhibitors, an HDC inhibitor: S(+)-alpha-fluoromethyl-histidine HCl, (alphaFMH), a compound that disturbs the interaction of histamine with intracellular cyp450 moieties: N,N-diethyl-2-[4-(phenylmethyl) phenoxy]-ethanamine HCI, (DPPE); and H1 and H2 receptor antagonists, Triprolidine and Cimetidine. RESULTS: During in vitro culture of elutriated human monocytes, in the presence of M-CSF, the gene expression and biosynthesis of HDC was considerably increased. The various antihistamine agents decreased the expression of the cell surface markers examined in this study. CONCLUSIONS: These data support the elevation of HDC expression during human monocytic differentiation and the possibility that monocyte-derived histamine is partially involved in regulation of M-CSF induced in vitro human monocyte/macrophage phagocytic differentiation.     

Autonomous histamine metabolism in human melanoma cells

Melanoma cells constitutively produce various cytokines as well as growth factors and express their corresponding receptors. Exogenous histamine is known to be a growth factor for some tumours while in other cases histamine inhibits tumour growth, and acts on G protein-coupled H1 and H2 histamine receptors. In previous studies we have detected the expression of the l-histidine decarboxylase (HDC) gene and the presence of HDC protein in human melanoma cell lines. In the present study, the activities of the histamine-forming enzyme HDC and of the degrading enzymes diamine oxidase (DAO) and histamine N-methyltransferase (HNMT) were measured in primary (WM35 and WM983) and metastatic (M1 and HT168) human melanoma cell lines. HDC activity was found in WM35 and WM983 cell lines, while detectable HNMT activity was measured in WM983, M1 and HT168 lines. In contrast, DAO showed very low activity in melanoma cell lines. Melanoma cells release a detectable amount of histamine into the medium without external stimuli. These findings support the possibility of autonomous histamine metabolism in melanoma cells. Our results suggest that not only exogenous histamine but also histamine produced and released by the melanoma cells and acting as an autocrine and paracrine factor may influence cell proliferation and modulate the in situ immune response of the host.     

Soluble interleukin-6 receptor enhanced by oncostatin M induces major changes in gene expression profile of human hepatoma cells

Interleukin-6 (IL-6) binds to a receptor complex consisting of an 80 kDa binding unit (IL-6R) and gp130 responsible for signal transduction. Due to alternative splicing and/or proteolytic digestion IL-6R occurs in soluble form (sIL-6R), as well. Soluble IL-6R is able to bind to gp130 expressing on nucleated cells, thus sIL-6R makes most cells responsive to IL-6. In this study we found that oncostatin M (OSM), an other gp130 dependent cytokine with proliferation inhibitory potential, increases the expression of both membrane-bound IL-6R and sIL-6R generated by alternative splicing in hepatic and mammary carcinoma cell lines. Furthermore, we studied the functional relevance of the presence and binding of soluble IL-6R to HepG2 cells. Using a cDNA expression array, mRNA levels of about 580 human genes were tested by differential display analysis. Our findings suggest, that elevation of surface density of IL-6R by attachment of sIL-6R induces major modulation in gene expression profile of the hepatoma cells. Soluble IL-6R alone has minor effect, it rather decreases expression of some genes, while incubation with IL-6 and sIL-6R together induces major changes in the mRNA pattern of HepG2 cells. These data strongly suggest that presence and binding of soluble cytokine receptors are important elements of inter-cytokine cross talk and affects actual gene expression profile of responding cells.     

Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101

Immunotherapy approaches focusing on T cells have provided breakthroughs in treating solid tumors. However, there remains an opportunity to drive anticancer immune responses via other cell types, particularly myeloid cells. ATRC-101 was identified via a target-agnostic process evaluating antibodies produced by the plasmablast population of B cells in a patient with non-small cell lung cancer experiencing an antitumor immune response during treatment with checkpoint inhibitor therapy. Here, we describe the target, antitumor activity in preclinical models, and data supporting a mechanism of action of ATRC-101. Immunohistochemistry studies demonstrated tumor-selective binding of ATRC-101 to multiple nonautologous tumor tissues. In biochemical analyses, ATRC-101 appears to target an extracellular, tumor-specific ribonucleoprotein (RNP) complex. In syngeneic murine models, ATRC-101 demonstrated robust antitumor activity and evidence of immune memory following rechallenge of cured mice with fresh tumor cells. ATRC-101 increased the relative abundance of conventional dendritic cell (cDC) type 1 cells in the blood within 24 h of dosing, increased CD8⁺ T cells and natural killer cells in blood and tumor over time, decreased cDC type 2 cells in the blood, and decreased monocytic myeloid-derived suppressor cells in the tumor. Cellular stress, including that induced by chemotherapy, increased the amount of ATRC-101 target in tumor cells, and ATRC-101 combined with doxorubicin enhanced efficacy compared with either agent alone. Taken together, these data demonstrate that ATRC-101 drives tumor destruction in preclinical models by targeting a tumor-specific RNP complex leading to activation of innate and adaptive immune responses.

Advances in immunotherapy have provided a breakthrough in cancer treatment by introducing options beyond the previous mainstay of cytotoxic chemotherapy and targeted molecular therapies (1). Antibodies that target immune checkpoint proteins, such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1), have been studied and approved for the treatment of various cancers (1, 2). While immune checkpoint inhibitors (ICIs) have shown promising results in various cancer types, not all patients benefit from treatment with some developing immune-related adverse events and the acquisition of resistance (3–9).The benefits of T-cell directed immunotherapy for a subset of patients with cancer has invigorated efforts to exploit the antitumor capabilities of other immune cells. Myeloid cells play a crucial role in the immune system’s ability to recognize self from nonself (10). One mechanism by which this effect is mediated is the recognition of nucleic acids in the extracellular environment by endosomal toll-like receptors (TLRs), which can activate dendritic cells (DC), leading to production and release of cytokines, such as type 1 interferon (10–12). Studies of TLR stimulation have shown antitumor effects through various mechanisms, including reducing myeloid-derived suppressor cells (MDSCs), activating natural killer (NK) cells, and inducing cytotoxic T cells (13–16). B cells also play a key role in the immune response, including maintaining innate immunity and producing proinflammatory and regulatory cytokines (17). Engaging multiple immune-cell types may represent a step forward for immuno-oncology therapies.During an immune response, antigen-activated B cells differentiate into plasmablasts and memory B cells (18). More than 75% of plasmablasts circulating in the peripheral blood express antibodies that are specific to antigens of the ongoing immune response (18); given their relatively short persistence in the bloodstream, blood plasmablasts can therefore provide insights into the antigens being actively processed by the immune system and the antibodies being generated by affinity maturation at a particular point in time (i.e., the immune repertoire) (18, 19). In addition, higher plasmablast levels have been reported in the blood of patients with nonprogressive metastatic cancer compared with healthy individuals (19). The analysis of plasmablasts collected from patients with ongoing antitumor responses enables the generation of antibody-based candidate cancer therapeutics and tumor targets through the interrogation of the human immune system to find potential targets. The antibodies produced by patients’ plasmablasts are screened to identify those that bind selectively to tumor tissues. ATRC-101 is a therapeutic candidate identified using this approach. Here we describe the identification and preclinical characterization of ATRC-101, which is currently in a phase 1b clinical trial in patients with advanced solid tumors.